An elamipretide clinical trial tests this investigational peptide in Barth syndrome, mitochondrial myopathy, and heart failure. Here's the status and results.
An elamipretide clinical trial is a human research study testing elamipretide, an investigational peptide also known as SS-31, MTP-131, or Bendavia. Trials have focused mainly on Barth syndrome, primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration. Elamipretide is not approved by the FDA for any indication, so it is available only through clinical trials or an expanded access program.
What Is Elamipretide and How Does It Work?
Elamipretide is a synthetic tetrapeptide that concentrates in the inner mitochondrial membrane, where it binds to cardiolipin. Cardiolipin helps organize the proteins of the electron transport chain, and the working theory is that stabilizing it improves energy production and lowers oxidative stress.
That mechanism is plausible and well studied in laboratory models, but mechanism is not the same as proven clinical benefit. Researchers designing an ss-31 clinical trial still have to show that a measurable change in mitochondrial function translates into something patients feel or doctors can measure, such as walking distance or cardiac function.
Which Conditions Have Been Studied in Elamipretide Clinical Trials?
Because mitochondrial dysfunction appears in many diseases, the drug has been tested across a wide range of conditions rather than a single target.
| Condition | Example Trial | Phase | Reported Outcome |
|---|---|---|---|
| Barth syndrome | TAZPOWER | Phase 2/3 | Improvements in some functional and cardiac measures; FDA declined approval |
| Primary mitochondrial myopathy | MMPOWER-3 | Phase 3 | Did not meet its primary endpoint |
| Heart failure | EMBRACE-HF, PROGRESS-HF | Phase 2 | Lower cardiac filling pressures in one study; no proven long-term benefit |
| Dry AMD / geographic atrophy | ReCLAIM, ReCLAIM-2 | Phase 2 | Mixed results; the larger study missed its primary endpoint |
| Leber's hereditary optic neuropathy | ReSIGHT | Phase 2 | Early-stage data only |
None of these elamipretide uses have cleared FDA review, and none should be described as a proven treatment. The Barth syndrome program has come closest to an approval decision.
How Are Elamipretide Trials Designed?
Most trials have used daily subcutaneous injections, often with an open-label extension so participants can keep treatment after the controlled phase ends. Common endpoints include:
- Functional capacity: six-minute walk test distance, grip strength, and fatigue scores.
- Cardiac measures: stroke volume, left ventricular ejection fraction, and pulmonary artery pressure.
- Disease-specific scales: the Barth syndrome symptom assessment and patient-reported global impression of change.
- Vision: best-corrected visual acuity and retinal imaging in the eye studies.
Rare-disease trials are hard to interpret because they enroll small numbers of patients, often without a placebo arm, and because symptoms fluctuate naturally. A short-term improvement in an open-label phase can look better than it really is once a control group is included.
What Have the Results Shown So Far?
Results have been inconsistent across programs. In Barth syndrome, the open-label phase showed gains in walking distance and some cardiac measurements, but the FDA issued a Complete Response Letter declining approval and asking for more evidence. The agency has not approved elamipretide for Barth syndrome or any other condition.
In primary mitochondrial myopathy, the Phase 3 MMPOWER-3 trial did not meet its primary endpoint. In heart failure, EMBRACE-HF reported a reduction in cardiac filling pressures, but none of the heart failure studies were large enough or long enough to prove that patients live longer or feel better.
Elamipretide has not yet demonstrated consistent, confirmatory benefit in a pivotal clinical trial.
Safety and Side Effects
Reported side effects are generally described as mild to moderate. The most common complaints in published trials include:
- Injection site reactions such as redness, pain, or swelling
- Headache
- Nausea
- Dizziness and fatigue
Long-term safety data remain limited, and because the drug is unapproved, no one can yet describe its full risk profile, including effects during pregnancy or alongside other medications. People who search where to buy bpc-157 peptide online run into the same problem: peptides sold outside clinical trials carry no guarantee of purity, dose, or sterility.
How to Find or Join an Elamipretide Clinical Trial
ClinicalTrials.gov is the best starting point because it lists recruiting studies, locations, and site contacts. The same registry also lists metabolic research such as cagrilintide clinical trials, which can help you see how listings are formatted before you start filtering.
Eligibility basics
Enrollment criteria vary by study, but common requirements include a genetically confirmed or clinically supported diagnosis, a specific age range, stable background medications, and the ability to travel to a study center for regular visits. Placebo-controlled trials mean that not every participant receives elamipretide.
Questions worth asking
- Is this study randomized, and could I receive a placebo?
- Who pays for travel, testing, and the drug itself?
- What happens when the trial ends — is there an extension or expanded access?
- What side effects have been seen so far in this specific protocol?
Patient advocacy groups for mitochondrial disease often summarize enrollment news on a clinical research blog, and study coordinators are usually willing to explain the visit schedule before you commit. Bring those details to your own physician, especially if you take medications that could interact.
For now, the honest summary is that elamipretide remains an investigational drug with a strong scientific rationale and an unproven clinical record. Anyone considering it should weigh the uncertainties with a qualified healthcare professional rather than relying on marketing claims or gray-market sellers.
Frequently Asked Questions
Is elamipretide approved by the FDA?
No. Elamipretide remains an investigational drug and is not approved by the FDA for Barth syndrome or any other indication. The agency has issued a Complete Response Letter for the Barth syndrome program and asked for additional evidence. Outside of clinical trials and expanded access, there is no legal supply of elamipretide in the United States.
What is elamipretide used for in clinical trials?
Trials have tested elamipretide in Barth syndrome, primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration, plus smaller studies in Leber's hereditary optic neuropathy. Results have been mixed, and no use has been confirmed in a pivotal trial. The Barth syndrome program is the furthest along in the review process.
How do I join an elamipretide clinical trial?
Start with ClinicalTrials.gov and filter for recruiting studies, then contact the study site directly for screening details. Most trials require a confirmed diagnosis and enrollment at a specific academic medical center. Your specialist can help you decide whether the eligibility criteria, visit schedule, and risks fit your situation.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.